CEA, CA 19‐9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice
Authors:
- 29 January 2007
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 95 (2) , 142-147
Abstract
Background and Objectives: In this study, the value of the serum tumor markers carcinoembryonic antigen (CEA), CA 19‐9, and CA 125 was assessed in the differential diagnosis of benign and malignant pancreatic diseases with and without obstructive jaundice.Methods: Serum levels of CEA, CA 19‐9, and CA 125 were measured by immunoradiometric assay before the treatment in 123 patients with pancreatic carcinoma and 58 patients with a benign pancreatic disease.Results: The sensitivity of CEA, CA 19‐9, and CA 125 in the diagnosis of pancreatic carcinoma was 39.0%, 81.3%, and 56.9%; and specificity was 91.4%, 75.9%, and 77.6%, respectively. Although there was no significant difference between the CA 19‐9 positivity ratios of the jaundiced (84.3%) and nonjaundiced (73.5%) patient subgroups of the pancreatic carcinoma, this ratio was significantly higher in the jaundiced subgroup (64.7%) than the nonjaundiced subgroup (7.3%) of the benign pancreatic diseases (P < 0.001). The CEA and CA 125 positivity ratios of jaundiced and nonjaundiced subgroups of patients with benign and malignant pancreatic diseases were not significantly different.Conclusions: In the differential diagnosis of pancreatic carcinoma from benign pancreatic diseases, CA 19‐9 can be useful in the nonjaundiced patients, whereas CA 125 provides a limited contribution in jaundiced patients. J. Surg. Oncol. 2007;95:142–147.Keywords
This publication has 18 references indexed in Scilit:
- Utility of Tumor Markers in Determining Resectability of Pancreatic CancerArchives of Surgery, 2003
- Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundiceEuropean Journal of Surgical Oncology, 2000
- Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitisCancer, 2000
- Diagnostic value of CA 19-9 in patients with pancreatic cancer and nonspecific gastrointestinal symptomsJournal of Gastrointestinal Surgery, 1997
- Carcinoembryonic antigen (CEA) and CEA-related substances in the bile of patients with biliary diseasesThe American Journal of Surgery, 1994
- Evaluation of a Serologic Marker, CA19-9, in the Diagnosis of Pancreatic CancerAnnals of Internal Medicine, 1989
- Comparative effectiveness of the tumour diagnostics, CA 19-9, CA 125 and carcinoembryonic antigen in patients with diseases of the digestive system.Gut, 1987
- Elevation of CA 125 in patients with benign and malignant ascitesCancer, 1987
- Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreasGastroenterology, 1986
- Elevated Carcinoembryonic Antigen Levels And Biliary Tract ObstructionJAMA, 1975